GSK’s TB vaccine makes a big step forward towards licensing

GSK's PARP drug Zejula approved in wider ovarian cancer popu...

The FDA has approved GlaxoSmithKline’s Zejula (niraparib) in a wider ovarian cancer indication, the first time a PARP class drug has been approved in a wider group of patients without the B

GSK sells travel vaccines to Bavarian Nordic

GlaxoSmithKline (GSK) has sold off two travel vaccines to Bavarian Nordic, as the company shifts its focus away from drugs it acquired through a multi-billion “asset swap” deal with Novarti

GSK’s Walmsley backs #MeTooPay gender pay campaign

FDA rejection scuppers AZ’s hopes of a COPD triple clash wit...

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l